InsiderTrades.com logo

FRX Insider Trading

Insider Ownership Percentage: 16.20%
Insider Buying (Last 12 Months): C$175,663.37
Insider Selling (Last 12 Months): C$14,568,602.92

Fennec Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Fennec Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fennec Pharmaceuticals Share Price & Price History

Current Price: C$15.24
Price Change: ▲ Price Increase of +0.24 (1.60%)
As of 06/26/2026 03:50 PM ET

This chart shows the closing price history over time for FRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Fennec Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/1/2026Rostislav Christov RaykovDirectorBuy15,597C$3.37C$52,561.892,755,851
6/1/2026Rostislav Christov RaykovDirectorSell9,747C$13.23C$128,952.812,746,104
5/11/2026Chris Anigeron RallisDirectorBuy14,344C$3.35C$48,052.4069,660
5/11/2026Chris Anigeron RallisDirectorSell8,346C$9.67C$80,705.8261,314
2/2/2026Rostislav Christov RaykovDirectorBuy15,598C$3.37C$52,565.262,719,643
2/2/2026Rostislav Christov RaykovDirectorSell10,349C$10.69C$110,630.812,709,294
12/24/2025Southpoint Capital Advisors LpInsiderSell1,000,000C$10.35C$10,350,000.002,744,741
11/17/2025Southpoint Capital Advisors LpInsiderSell85,918C$12.35C$1,061,087.303,764,082
11/14/2025Southpoint Capital Advisors LpInsiderSell160,100C$11.24C$1,799,524.003,850,000
10/10/2025Chris Anigeron RallisDirectorBuy4,062C$1.70C$6,905.4057,091
10/10/2025Chris Anigeron RallisDirectorSell1,775C$12.75C$22,631.2555,316
10/9/2025Southpoint Capital Advisors LpInsiderSell20,609C$12.89C$265,650.014,010,100
10/8/2025Rostislav Christov RaykovDirectorBuy4,609C$3.38C$15,578.422,697,927
10/8/2025Southpoint Capital Advisors LpInsiderSell19,605C$13.07C$256,237.354,030,709
10/7/2025Southpoint Capital Advisors LpInsiderSell26,900C$13.23C$355,887.004,050,314
7/7/2025Chris Anigeron RallisDirectorSell1,119C$11.93C$13,352.69
7/7/2025Chris Anigeron RallisDirectorSell2,127C$3.22C$6,847.88
7/3/2025Rostislav Christov RaykovDirectorSell10,000C$11.71C$117,096.00
6/5/2025Rostislav Christov RaykovDirectorSell10,000C$10.66C$106,586.00
6/2/2025Robert Christopher AndradeSenior OfficerBuy8,220C$6.99C$57,433.14
5/19/2025Jeffrey HackmanDirectorBuy15,000C$9.77C$146,580.00
5/16/2025Rostislav Christov RaykovDirectorSell16,667C$9.49C$158,203.16
4/11/2025Chris Anigeron RallisDirectorSell1,409C$6.93C$9,764.37
4/4/2025Rostislav Christov RaykovDirectorSell10,000C$7.46C$74,550.00
3/5/2025Rostislav Christov RaykovDirectorSell7,569C$9.71C$73,503.54
2/14/2025Chris Anigeron RallisDirectorSell1,186C$9.68C$11,485.70
2/5/2025Rostislav Christov RaykovDirectorSell2,431C$9.66C$23,476.17
1/6/2025Rostislav Christov RaykovDirectorSell10,000C$8.76C$87,552.00
12/20/2024Rostislav Christov RaykovDirectorBuy25,000C$3.87C$96,840.00
12/5/2024Rostislav Christov RaykovDirectorBuy796C$8.52C$6,779.05
11/18/2024Robert Christopher AndradeSenior OfficerBuy15,816C$3.43C$54,248.88
10/8/2024Chris Anigeron RallisDirectorSell1,406C$6.16C$8,662.08
10/2/2024Rostislav Christov RaykovDirectorSell2,431C$6.67C$16,212.34
9/4/2024Rostislav Christov RaykovDirectorSell2,431C$7.45C$18,115.81
7/5/2024Chris Anigeron RallisDirectorSell1,173C$6.03C$7,073.19
7/1/2024Rostislav Christov RaykovDirectorSell2,431C$6.13C$14,902.03
4/23/2024Adrian J. HaighSenior OfficerSell22,223C$9.32C$207,029.47
4/15/2024Adrian J. HaighSenior OfficerBuy22,222C$2.31C$51,332.82
4/15/2024Chris Anigeron RallisDirectorSell800C$10.45C$8,360.00
3/26/2024Chris Anigeron RallisDirectorSell2,114C$10.97C$23,190.58
3/26/2024Robert Christopher AndradeSenior OfficerSell13,975C$10.90C$152,345.67
11/24/2023Chris Anigeron RallisDirectorSell269C$8.25C$2,219.25
11/16/2023Khalid IslamDirectorBuy20,492C$2.44C$50,000.48
11/3/2023Rostislav Christov RaykovDirectorBuy74,793C$1.59C$118,920.87
See Full Table

SEC Filings (Institutional Ownership Changes) for Fennec Pharmaceuticals (TSE:FRX)

12.57% of Fennec Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Fennec Pharmaceuticals logo
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in the U.K. and Germany. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection.
Read More on Fennec Pharmaceuticals

Today's Range

Now: C$15.24
Low: C$14.95
High: C$15.24

50 Day Range

MA: C$11.83
Low: C$8.45
High: C$15.24

52 Week Range

Now: C$15.24
Low: C$7.59
High: C$15.24

Volume

2,926 shs

Average Volume

1,350 shs

Market Capitalization

C$529.39 million

P/E Ratio

N/A

Dividend Yield

2.02%

Beta

3.518081

Who are the company insiders with the largest holdings of Fennec Pharmaceuticals?

Fennec Pharmaceuticals' top insider shareholders include:
  1. Rostislav Christov Raykov (Director)
  2. Southpoint Capital Advisors Lp (Insider)
  3. Robert Christopher Andrade (Senior Officer)
  4. Chris Anigeron Rallis (Director)
  5. Adrian J Haigh (Senior Officer)
  6. Jeffrey Hackman (Director)
  7. Khalid Islam (Director)
  8. SPA Essetifin (Insider)
Learn More about top insider investors at Fennec Pharmaceuticals.